Vaccines against Tuberculosis: Where Are We Now?
Tuberculosis (TB) is among the top 10 leading causes of death in low-income countries. Statistically, TB kills more than 30,000 people each week and leads to more deaths than any other infectious disease, such as acquired immunodeficiency syndrome (AIDS) and malaria. TB treatment is largely dependen...
Main Authors: | Shruti Srivastava, Sajal Dey, Sangita Mukhopadhyay |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/11/5/1013 |
Similar Items
-
Preclinical Progress of Subunit and Live Attenuated <i>Mycobacterium tuberculosis</i> Vaccines: A Review following the First in Human Efficacy Trial
by: Jacqueline Watt, et al.
Published: (2020-09-01) -
Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions
by: Deepshikha Verma, et al.
Published: (2020-11-01) -
Immunological Interactions between Intestinal Helminth Infections and Tuberculosis
by: Khethiwe Nomcebo Bhengu, et al.
Published: (2022-11-01) -
HUBUNGAN RIWAYAT STATUS IMUNISASI BACILLE CALMETTE-GUÉRIN (BCG) DENGAN KEJADIAN TUBERKULOSIS (TB) PADA ANAK DI BADAN LAYANAN UMUM DAERAH RUMAH SAKIT UMUM CUT MEUTIA ACEH UTARA TAHUN 2015
by: Hedya Nadhrati Surura, et al.
Published: (2018-02-01) -
Clinical Development of New TB Vaccines: Recent Advances and Next Steps
by: Mark Hatherill, et al.
Published: (2020-01-01)